Drug Trial Radar · NCT05835479
Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
Last checked: Nov 19, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Nov 14, 2023
Primary completion
May 2025
Study completion Aug 2025
Sponsor
- Lead sponsor
- Mundipharma Research LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to generate clinical data on the efficacy, safety, and tolerability of rezafungin combined with 7 days of co-trimoxazole for treatment of Pneumocystis pneumonia (PCP) in adults living with human immunodeficiency virus (HIV), which would expand the knowledge of clinical use of rezafungin.
Conditions
- Pneumocystis Pneumonia
Interventions
Co-TrimoxazoleDrug
Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication
Rezafungin Acetate / Co TrimoxazoleDrug
Rezafungin for infusion. Intravenous anti fungal therapy Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Therapeutic failure on Day 8Time frame: 8 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Cape Town
Cape Town, South Africa · Recruiting
Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, South Africa · Recruiting
Helen Joseph Hospital
Johannesburg, South Africa · Terminated
Global Clinical Trials - Pretoria
Pretoria, South Africa · Recruiting
Steve Biko Academic Hospital
Pretoria, South Africa · Recruiting
Netcare Umhlanga Medical Centre
Umhlanga, South Africa · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.